ImmunoGen, Inc. Announces Conference Call to Discuss its Second Quarter Fiscal Year 2016 Financial Results
To access the live call by phone, dial 913-312-0836; the conference ID
is 5851737. The call also may be accessed through the Investors section
of the Company's website, www.immunogen.com.
Following the live webcast, a replay of the call will be available at
the same location through
About
ImmunoGen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics with its proprietary ADC technology. The Company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancers and other solid tumors. A number of major healthcare companies have licensed limited rights to use ImmunoGen's ADC technology to develop novel anticancer therapies; it is used in Roche's marketed product, Kadcyla®. More information about the Company can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the Roche Group.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160120005197/en/
info@immunogen.com
Source:
News Provided by Acquire Media